ERBB2 and neoplasm: For example, Debie et al. demonstrated in vivo, using intravital fluorescence microscopy, that monomeric nanobodies rapidly extravasate and distribute homogenously throughout HER2-positive tumor tissue within minutes post-injection, achieving maximal tumor uptake significantly faster than trastuzumab, which exhibited slower, perivascular, and heterogeneous distribution even after 24 h.